A Prospectively Randomized Trial of Low-Dose Leucovorin Plus 5-FU, High-Dose Leucovorin Plus 5-FU, Levamisole Plus 5-FU, or Low-Dose Leucovorin Plus 5-FU Plus Levamisole Following Curative Resection in Selected Patients with Duke's B or C Colon Cancer
Research committees
Publication Information Expand/Collapse
2005
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089
2002
Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089
Outcomes and toxicity in African-American and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer.
2001
Outcomes and toxicity in African-American an d caucasian patients receiving adjuvant chemotherapy for colon cancer: a secondary analysis of INT-0089
2000
Colon cancer survival is associated iwth increasing number of lymph nodes removed. a secondary analysis of INT-0089
1999
Surveillance for second primary colon cancers after adjuvant chemotherapy: analysis of INT-0089
1998
Fluorouracil (FU), leucovorin (LV), and levamisole (LEV) adjuvant therapy for colon cancer: Five-year final report of INT-0089.
1997
Thymidylate synthase expression as a predictor for response to 5-fluorouracil-based therapy and survival for patients (pts) with resected colon or advanced colorectal cancer. An ECOG study.
Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: four year results of INT-0089
1996
Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Preliminary results of INT-0089.